Lundbeckfonden Ventures took a board seat at VarmX as part of a $36.2m round that will fund development of a treatment for spontaneous bleeding.
Netherlands-based anticoagulation therapy developer VarmX closed a €32m ($36.2m) series B round yesterday that included Lundbeckfonden Ventures, the corporate venture capital arm of pharmaceutical firm Lundbeck.
Venture capital firms Ysios Capital and Inkef Capital co-led the round, which also featured fellow VC firm BioGeneration Ventures (BGV) as well as life sciences investment firm LSP and InnovationQuarter, West Holland’s regional development agency.
VarmX is developing a treatment for patients who suffer spontaneous bleeding when being treated with oral factor Xa inhibitors…
